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Objective: This study evaluated long-term results of radiofrequency ablation for medically inoperable early–
stage lung cancer.
Methods: Thirty-one consecutive patients with biopsy-proven non–small cell lung cancer underwent 38 treat-
ments of computed tomographically guided radiofrequency ablation in a 4.5-year period. All patients were care-
fully selected and deemed medically ineligible for resection by a multidisciplinary team. Radiofrequency ablation
was performed with curative intent with a single or cluster cool-tip electrode. Patients were hospitalized for
23-hour observation.
Results: Treatment was complete in all cases, with no 30-day mortality. Local recurrence was confirmed radio-
graphically by computed tomography, positron emission tomography, or both after 31.5% of treatments (12/38).
Two patients were successfully retreated for technical failures related to pneumothorax; 3 underwent radiotherapy
with stable disease. Mean maximal diameter of 38 tumors treated was 2.0  1.0 cm (range 0.8–4.4 cm). After
median follow-up of 17  11 months, 74% of patients (23/31) were alive. Three patients died of metastatic dis-
ease; 5 died of pneumonia remote from treatment. The 2- and 4-year survivals were 78% and 47%, respectively.
Median overall survival was 30 months. Pneumothorax (13%), pneumonia (16%), and pleural effusion (21%),
were the most common complications.
Conclusions: Radiofrequency ablation of medically inoperable early–stage lung cancer in carefully selected
patients yields encouraging midterm results without significant loss of pulmonary function. Local tumor progres-
sion appears related to lung tumors larger than 3 cm. Computed tomography and positron emission tomography
need further validation for the early identification of local tumor progression following radiofrequency ablation.Alternative therapy for unresectable stage I non–small cell
lung cancer (NSCLC) has historically been conventional
external beam radiotherapy (XRT), with only modest long-
term local control.1,2 In a meta-analysis of 26 nonrandom-
ized studies treating inoperable stage I or II NSCLC with
high-dose XRT, 3-year survival and local failure rates
were 17% to 55% and 6% to 70%, respectively.3 Tradi-
tional surgical therapy for early–stage lung cancer may not
be feasible because of significant cardiopulmonary compro-
mise or a patient’s refusal of surgical intervention. Newer
nonsurgical modalities include bioimage-guided 4-dimen-
sional radiation, stereotactic radiotherapy,4 and lung radio-
frequency ablation (RFA). There has been accumulating
experience from a number of investigators that lung RFA
is safe and feasible for the treatment of unresectable stage
I lung cancer.5-9 Limitations of this technology for solid
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blood vessels.
Because there have been no randomized, controlled trials
assessing long-term outcome of newer radiation techniques
versus RFA for lung cancer, these modalities must be care-
fully scrutinized. There is no standardization of lung RFA,
and many of the reported series used different RFA systems.
The clinical efficacy of tumor destruction with different RFA
systems has not been formally compared. Regional disease
progression is often poorly characterized in contemporary se-
ries, because hilar and mediastinal lymph nodes are evaluated
by imaging studies and not pathologic verification.
In this study, we evaluated the outcomes of stage I
NSCLC treated with a single RFA system and highlighted
local control, patterns of failure, complications, and changes
in pulmonary function. Positron emission tomography
(PET) was also implemented in the detection of local tumor
progression.
MATERIALS AND METHODS
Subject Selection
The study population included consecutive patients with NSCLC under-
going lung RFA from July 2003 to February 2008 at the Massachusetts Gen-
eral Hospital. All participants were evaluated by a multidisciplinary team
including representatives from medical oncology, radiation oncology, tho-
racic surgery, and thoracic radiology. Patients with NSCLC had clinical
staging with chest computed tomography (CT) and PET scan within 60
days of evaluation. Patients with fluorodeoxyglucose-avid mediastinalrgery c January 2009
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TAbbreviations and Acronyms
CT ¼ computed tomography
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
RFA ¼ radiofrequency ablation
XRT ¼ external beam radiotherapy
lymph nodes or lymph nodes larger than 1.0 cm in short-axis diameter were
evaluated by mediastinoscopy. Medical inoperability was determined by
a thoracic surgeon according to advanced cardiopulmonary morbidities:
(1) compromised pulmonary function, measured as forced expiratory vol-
ume in 1 second less than 40% predicted, diffusion capacity of carbon mon-
oxide less than 50% predicted, or oxygen desaturation with climbing one
flight of stairs; (2) severe vascular disease; (3) high cardiac risk, including
unstable angina or ejection fraction less than 30%; and (4) poor perfor-
mance status (Zubrod score of 2 to 3). Patients with PET-positive or en-
larged N1 nodes within the same lobe of the lesion were excluded from
RFA treatment. Inclusion criteria for lung RFA were as follows: tumors
that were medically inoperable, tumor size smaller than 4 cm, no evidence
of extraregional (outside of the involved lobe) disease, or patient refusal of
surgery because of elevated risk profile. Before lung RFA, all lesions under-
went biopsy with CT-guided fine-needle aspiration to confirm the diagnosis.
RFA treatment was performed at a separate setting after informed, written
consent had been obtained. Approval for this retrospective study was
granted by the institutional review board at the Massachusetts General
Hospital.
RFATreatment
All lung RFA treatments were performed percutaneously with a single or
cluster cool-tip electrode coupled to a generator and perfusion pump
(Covidien, Mansfield, Mass). Procedures were performed with CT guidance
(64-slice CT; Siemens Corp, New York, NY) with 2.5-mm collimation.
Although some patients received general anesthesia because of severe
cardiac or pulmonary compromise, conscious sedation with local anesthesia
was the preferred method. The cluster electrode was implemented for
lesions larger than 1 cm, whereas the single electrode was used for lesions
1 cm or smaller. Once in place, a 12-minute RFA treatment was initiated,
during which the patient was closely monitored for adequate pain control,
respiration, and oxygenation. After this time, temperature within the lesion
was measured to achieve more than 60C (usually about 90C) for the ab-
lation to be considered adequate. Before the electrode was removed, a CT
scan was performed to assess for an adequate margin of treatment, which
was seen as a ground-glass opacity surrounding the tumor, and to detect
any immediate complications, such as hemothorax, pneumothorax, or pul-
monary hemorrhage. If necessary, the electrode was repositioned and an
additional treatment performed.
Patients were admitted overnight for 23-hour observation and prescribed
oral analgesic narcotics to treat any pleuritic pain after the procedure. In ad-
dition, prophylactic antibiotics were administered to patients with prosthetic
cardiac valves, pacemakers, mitral valve prolapse, or joint prostheses. Pa-
tients were instructed to watch for the onset of fever or sputum production,
which could signal the development of pneumonia.
Pulmonary function was routinely measured a few months before sched-
uled RFA and then 3 to 6 months after treatment. Imaging follow-up was
performed to assess for treatment efficacy and local tumor progression.
PET with diagnostic quality CT was performed after 1, 6, 12, and 24 months
to help define its role in the early identification of local tumor progression.
Additional CT scans were obtained at 3, 9, and 18 months. If there was
evidence of disease progression, repeated RFA was considered.The Journal of Thoracic andLocal control was defined as lack of focal or diffuse enlargement of the
ablated lesion on CT and no evidence of eccentric enhancement on PET at
a minimum of 3 months of follow-up. Progression of fluorodeoxyglucose-
avid regional lymphadenopathy (hilar or mediastinal) after 3 months was
also considered a local failure.
Statistical Methods
Survival curves for overall, disease-free, and local tumor progression–
free survivals were constructed with the Kaplan–Meier method and com-
pared with the log rank test. Continuous variables were analyzed with the
Student t test and confirmed with the Mann—Whitney U test. The statistical
software package SPSS 14.0 (SPSS Inc, Chicago, Ill) was used for all sur-
vival analyses.
RESULTS
Thirty-one patients with 34 tumors underwent 38 lung
RFA treatments for clinical stage I NSCLC from July
2003 to February 2008. The mean maximal tumor diameter
was 2.0  1.0 cm (range 0.8–4.4 cm). Other patient charac-
teristics are described in Table 1. The majority of lung
tumors were adenocarcinomas, clinical T1N0. More than
half of the patients had a remote history of resected NSCLC,
contributing to their limited pulmonary function. Three pa-
tients had more than 1 tumor considered to be synchronous
or metachronous primary lung cancers.
Inoperability was determined by clinical parameters or
the patients desire to avoid surgery in association with their
medical comorbidities. Limited pulmonary function was
TABLE 1. Patient and tumor characteristics (N ¼ 31)
Sex (female/male) 17:14
Age (y, median) 70
Lesion size (cm)
Mean  SD 2.0  1.0
Range 0.8–4.4
Previous lung cancer (No.) 17 (55%)
Zubrod score (No.)
0 9
1 14
2 7
3 1
Anesthesia
Conscious sedation 24
General 7
Clinical stage (N ¼ 34 tumors)
T1N0 29
T2N0 5
Histologic type
Squamous
No. 4
Mean tumor size (cm) 2.9
Adenocarcinoma
No. 20
Mean tumor size (cm) 1.9
Bronchoalveolar carcinoma
No. 10
Mean tumor size (cm) 1.9Cardiovascular Surgery c Volume 137, Number 1 161
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ity in 17 patients (55%). Eleven patients (35%) with medi-
cal comorbidities and preserved pulmonary function refused
surgery because of elevated surgical risk. Three patients
(10%) had significant cardiac or vascular disease that put
them at high risk with surgical intervention.
Pneumonia, pneumothorax, minor hemoptysis, and pleu-
ral effusion were the most common complications, as listed
in Table 2. All pneumonias occurred within 4 weeks of ab-
lation and resolved with a course of oral antibiotics. Periph-
eral cavities with air-fluid levels (representing limited
bronchopleural fistula) were observed in 3 patients; these ul-
timately resolved with observation. One patient had transient
right recurrent laryngeal nerve palsy as a result of thermal in-
jury from treating a right upper lobe tumor in proximity to
the anterior mediastinum. There was no major episodes of
hemoptysis or pulmonary hemorrhage in this series.
Local tumor progression after RFA was observed in 31.5%
of treated tumors (12/38). The average tumor size in patients
with local treatment failure was 2.3 1.0 cm, versus 1.8 0.9
cm in those with no recurrence (P¼ .15). Tumors larger than
3.0 cm had the highest local recurrence rate (50%), whereas
tumors smaller than 2.0 cm had the lowest (Table 3). Seventy-
five percent of the tumors that had local failure (9/12) were
recognized within 6 months of the original treatment. Two pa-
tients were successfully retreated early for technical failure re-
lated to procedure-related pneumothorax. Three patients had
local progression that subsequently responded to XRT with
stable disease. Another patient with a slow-growing lung can-
cer, who had initially refused surgery after previous pulmo-
nary resections, had local recurrence 17 months after RFA
and underwent a salvage right upper lobectomy. His final
pathologic examination showed a 1-cm residual adenocarci-
noma (T1N0M0) with extensive hyaline fibrosis, consistent
with treatment effect. Ninety percent of patients with a diag-
nosis of bronchoalveolar carcinoma (9/10, mean tumor size
TABLE 2. Summary of complications for 38 treatments
No. %
Pneumothorax 5 13
Chest tube insertion 3 8
Minor hemoptysis 6 16
Hemothorax 2 5
Pneumonia (within 30 d) 6 16
Pleural effusion 8 21
Neuropathy 1 3
Bronchopleural fistula 3 8
TABLE 3. Summary of local tumor progression by size
Tumor size (cm) No. of lesions Local recurrence (%)
0–1.9 23 21.7%
2.0–3.0 9 44.4%
>3.0 6 50.0%162 The Journal of Thoracic and Cardiovascular Su1.9 0.6 cm) showed no evidence of local tumor progression
at a median follow-up of 10.5  15 months.
Treatment was successfully performed in all cases with
no 30-day mortality. Seventy-four percent of patients (23/
31) were alive after a median follow-up of 17.3 11 months
(Table 4). Five patients died of respiratory complications
(pneumonia) related to chronic obstructive pulmonary dis-
ease, and 3 died of disseminated progression of lung cancer.
The overall 2- and 3-year survivals (Figure 1) were 78% and
47%, respectively. Median overall and disease-free sur-
vivals were 30 months and 25.5 months, respectively. Dis-
ease-free survivals (Figure 2) were 57% at 2 years and
39% at 3 years. Mean local tumor progression-free survival
was 33  3.8 months (Figure 3). Median local tumor pro-
gression-free survival was not reached. Tumors smaller
than 2 cm were associated with better local progression–
free survival than were larger tumors (Figure 4), although
not statistically significantly so (P ¼ .213).
Pulmonary function was evaluated in 23 patients before
and 3 to 6 months after treatment (Table 5). There was no
difference in both measured forced expired volume at 1 sec-
ond and diffusion capacity.
TABLE 4. Characteristics of 34 lesions treated with lung radio-
frequency ablation
Treatments (No.) 38
Repeat treatments (No.) 4
Local failure (No.) 12 (31.5%)
Alive (No.) 23 (74%)
Disease free (No.) 17 (74%)
Disease progression (No.) 6/23 (26%)
Follow-up (mo, median  SE) 17.3  11
Overall survival (mo, median  SE) 30  1.5
Local recurrence–free survival (mo, mean  SE) 33  3.8
FIGURE 1. Overall survival (1-year 85%, 2-year 78%, 3-year 47%).rgery c January 2009
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Surgical resection remains the mainstay for early–stage
NSCLC and provides the best chance for cure.10,11 High-
risk patients with limited cardiopulmonary reserve or poor
performance status, however, require alternative treatment
strategies. The major advantages of RFA therapy for the
treatment of medically unresectable stage I NSCLC are
low morbidity, single application, reduced hospital stay,
and well-defined zones of tissue destruction. In contrast,
conventional radiotherapy and stereotactic radiotherapy
FIGURE 2. Disease-free survival (1-year 82%, 2-year 57%, 3-year 39%).
FIGURE 3. Local progression–free survival (1-year 71%, 2-year 58%,
3-year 58%).The Journal of Thoracic and Crequire multiple treatments and are often associated with
pneumonitis, bronchial stenosis, esophagitis, and complica-
tions of fiducial markers. Long-term outcomes of stereotac-
tic radiotherapy in North America and Japan are still being
accumulated, but some reports indicate 2-year local control
rates of 63% to 95% (2-year survival about 55%) with
high-dose fractions but significant late toxicity, reported as
radiation pneumonitis, particularly in central tumors.4,12-14
In a recent review of 17 studies examining case series of
RFA for lung tumors, Zhu and associates15 highlighted
many of the challenges that make comparisons and data
analysis difficult. Aside from the implementation of differ-
ent RFA systems, there is no uniformity in RFA treatment
responses, patient populations and tumor characteristics
are heterogeneous, the definitions of local tumor progression
and radiologic assessment are variable, and patient follow-
up remains short. Fernando and colleagues5 attempted to
standardize treatment response by using modified response
evaluation criteria in solid tumors (RECIST), but these crite-
ria have not been widely accepted in RFA literature. In our
FIGURE 4. Local progression–free survival stratified by tumor size.
TABLE 5. Measured pulmonary function in 23 patients after lung
ablation
Parameter Preablation Postablation (3–6 mo)
Forced expiratory
volume in 1 s (L, mean  SD)
1.58  0.71 1.59  0.66*
Percentage of predicted
forced expiratory volume
in 1 s (mean  SD)
62.2%  25% 61.4%  25%y
Percentage of predicted
carbon monoxide lung
diffusion capacity (mean  SD)
56%  25% 55.8  22%
*By t test, P ¼ .39. yBy t test, P ¼ .26.ardiovascular Surgery c Volume 137, Number 1 163
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hanced by comparing PET characteristics of the ablated
lesion at 1, 6, and 12 months (the time at which 75% of
the lesions in this study had local failure). Characteristics
of local failure were defined by eccentric activity on PET
or lack of expected contraction of the ablated zone on chest
CT over time.
The American College of Surgeons is sponsoring a multi-
institutional phase I study (ASOSOG Z4033) to address uni-
formity of RFA treatment in high-risk patients with stage IA
NSCLC. Primary objectives are to establish 2-year survival,
to assess freedom from local and regional recurrence, to as-
sess the role of PET in predicting local control, and to explore
short- and long-term effects of RFA on pulmonary function.
Although we were unable to evaluate pulmonary function in
our entire study cohort, this report is the first to demonstrate
no statistically discernible difference in lung spirometry or
diffusion capacity (N ¼ 23) at 3 to 6 months after ablation.
Despite higher than expected mean values for percentage
predicted forced expiratory volume in 1 second (62%) and
diffusion capacity of carbon monoxide (56%) in this patient
series, many lesions were considered medically unresectable
because of cardiac comorbidities (eg, critical aortic stenosis,
coronary artery disease, cardiomyopathy), and 35% of pa-
tients refused surgery. Patients were selected for RFA on
the basis of anatomic criteria, mostly influenced by periph-
eral location and size 3 cm or smaller. Central lesions were
more likely to be referred for radiation therapy. The authors
found that referrals for RFA were also partly patient driven,
with high-risk patients favoring a single treatment modality
rather than multiple treatments.
In studies that treated early–stage NSCLC with RFA, local
tumor progression ranged from 3% to 42%.6,7,16,17 We ob-
served a 31.5% local tumor progression rate at 17 months after
RFA. Factors that have been reported to influence local failure
include tumor size; proximity to pulmonary vessels, aorta, or
azygous vein, which is associated with a ‘‘heat sink’’ effect;
and a satisfactory margin of ablation at least 1 cm beyond
the edge of tumor. The importance of ablation beyond the tu-
mor margin was eloquently evaluated by separate investiga-
tors with porcine and rabbit models of lung RFA.18,19 These
investigators demonstrated that there were three concentric
histologic zones of ablation (central, intermediate, and periph-
eral) with mixed populations of cells. The central and interme-
diate zones contained nonviable cells, whereas the peripheral
edge of ablation (2–5 mm) contained both necrotic and viable
cells, suggesting the technical need for RFA well beyond the
edge of tumor. These investigators also reported that the
ground-glass attenuation observed on CT corresponded to
all three zones and therefore would overestimate the diameter
of complete necrosis. Limitations of RFA technology for lung
neoplasm can potentially be addressed with combined modal-
ity treatment (RFA followed by XRT), because central tumor
hypoxia responds better to ablation.20164 The Journal of Thoracic and Cardiovascular SuThere was no 30-day mortality in our patient series, and
there were no complications requiring prolonged hospitali-
zation or significant additional medical intervention. Al-
though pleural effusions were relatively common (21%),
none required drainage. Pneumothorax in this series was
less common (13%) than in other published series, which
is potentially attributable to pleural symphysis as a result
of previous lung surgery in about 50% of the patients. Tran-
sient recurrent laryngeal nerve palsy, as observed in 1 patient
after upper lobe RFA, has been previously described.21
Because many patients with medically unresectable stage
I NSCLC have severe comorbidities, overall survival after
lung RFA is an inappropriate surrogate for treatment suc-
cess. Only 3 of the 8 patients in this study who died did so
of complications related to malignant disease progression,
whereas the remaining 5 of 8 died of complications of their
medical comorbidities remote to the time of RFA ablation,
emphasizing the compromised medical condition of these
selected patients. Freedom from local and regional progres-
sion is a far superior method of analyzing RFA outcome. We
observed estimated 3-year progression-free and disease-free
survivals of 58% and 39%, respectively, at a median fol-
low-up of 17 months (range 3–35 months). Although direct
comparison is difficult with small patient numbers, limited
or sublobar resection in compromised patients for T1N0
NSCLC in North America and Europe has a 3-year disease
free survival of about 60%.11,22 RFA for stage I NSCLC
is still considered a compromise and should not be
substituted for anatomic surgical resection, which currently
offers the best long-term survival.
Patterns of local or systemic recurrence after RFA of solid
tumors have not been thoroughly evaluated in published se-
ries. Acceleration of metastatic disease after liver RFA has
been considered,23 but this phenomenon has not been stud-
ied in the lung RFA experience. In an experience of more
than 50 RFA treatments of solid tumors in lungs (even in pa-
tients with post-RFA pleural effusions), we have not docu-
mented any pleural dissemination of metastatic disease
with the Covidien probe. The patterns of extraregional dis-
ease progression (listed in Table 6) are commonly seen in
the treatment of primary lung cancer, but no conclusions
can be derived regarding acceleration of malignant disease
TABLE 6. Pattern of disease progression after radiofrequency
ablation
Metastatic site No.
Ipsilateral lung 3
Contralateral lung with multifocal bronchoalveolar carcinoma 3
Liver 3
Bone 3
Brain 1
Ipsilateral regional lymph nodes 2rgery c January 2009
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sublobar resection.
We recognize that this is a prospective, observational
study with limited patient numbers and relatively short fol-
low-up. This is also a highly selected patient population sub-
ject to the institutional biases of the multidisciplinary team.
Unlike previous series, we did not use multiple RFA systems
to deliver treatments. Because 3 patients received conven-
tional XRT to lesions for which RFA had failed, firm conclu-
sions regarding outcome in these cases is confounded.
In summary, experience with RFA for stage I NSCLC is
accumulating. Intermediate results are encouraging and rival
the local control observed with conventional XRT. As newer
noninvasive alternatives emerge for medically inoperable
tumors, our ability to accurately stage cancers becomes
even more critical. One should emphasize the need for tho-
racic surgeons to be involved in the clinical decisions for
these difficult cases. Invasive staging modalities, such as
mediastinoscopy and endobronchial or endoesophageal
ultrasonography should be used for biopsy of suspect hilar
or mediastinal lymph nodes. Determination of response to
treatment and detection of local failure require careful
evaluation with anatomic (diagnostic CT) and functional
(PET) imaging by institutions experienced with RFA.
We acknowledge our research coordinators, Emily Nohrden,
MPH, and JoAnne Martino, RN, for compiling some of the data.
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Discussion
Dr Neil A. Christie (Pittsburgh, Pa). Lanuti and colleagues at
Massachusetts General Hospital should be commended for the ex-
ecution of the study. They are first to be commended for having tho-
racic surgeons participating both in the selection of these patients
and also in the application of the treatment, because it is important
that surgeons be involved. They are second to be commended both
for carefully evaluating their results and for presenting them now.
These newer ablative therapies, such as RFA and stereotactic radio-
surgery, are being widely promoted by radiologists and radiation
oncologists as alternative nonoperative but potentially curative
therapies for early-stage lung cancer. Earlier this week, Dr Roth
presented a multi-institutional study in which patients with opera-
ble early-stage lung cancer were randomly assigned to undergo ei-
ther surgery or ablative therapy with stereotactic radiosurgery for
lung cancers as large as 5 cm in diameter. So I think that as people
are starting to propose these therapies as curative therapy in opera-
tive candidates, it is important that we evaluate them and determine
their limitations.
In his presidential address at this meeting, Dr Craig Miller em-
phasized the importance to cardiothoracic surgeons of training
and participating in such novel nonsurgical therapies. He proposedardiovascular Surgery c Volume 137, Number 1 165
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Ta revision to the cardiac training program that would allot almost
equal time to surgical training and to novel, catheter-based therapy.
At the University of Pittsburgh, we have a hybrid operating room
where we do procedures such as RFA, and it is an integral part of
our training program. I think that it is highly likely in the future
that there will be a subset of patients with early-stage lung cancer
who, after careful staging, will receive adequate treatment with
nonsurgical ablative therapy instead of surgery. For all these rea-
sons, this is a timely report.
The study demonstrated that the therapy was safely adminis-
tered. There were no deaths, hospitalization was less than 24 hours,
and chest tube placement was required in only 8% of patients. It
also demonstrated maintenance of pulmonary function after ther-
apy, and 3-year progression-free survival was 58%. Overall, how-
ever, there was a 31.5% local recurrence rate, despite a relatively
small mean tumor diameter of 2 cm. In fact, tumors larger than 3
cm had a 50% local recurrence rate.
Dr Lanuti, you have discussed the difficulty in assessing these
patients in terms of response to therapy and also recurrence rate,
and that brings me to my first question. Please comment in a little
more detail on how you have addressed posttreatment follow-up?
You did use CT scans and PET scans. Did you find concordance
between those two studies, and to what extent did you confirm
your suspected recurrence with needle biopsy?
Dr Lanuti. All recurrences were confirmed by imaging studies
and, on a single occasion, transthoracic needle biopsy. Methods of
local recurrence detection included diagnostic CT and fluorodeox-
yglucose PET, with relative comparisons among the studies with
time. We found 9 of the 12 recurrences in less than 6 months. I think
that CT and PET alone are not as valuable as they are together. Pa-
tients did not routinely undergo biopsy to confirm the radiograph-
ically determined recurrence. No other modalities were used for
detection of local recurrence.
Dr Christie. Our experience at Pittsburgh with both RFA and
stereotactic radiosurgery has been that postoperative imaging can
be hard to interpret. We too have been using PET and CT, and often
we will take the first posttreatment study as a baseline to compare
other studies. We have been liberal with the use of biopsy, however,
especially as we are trying to ascertain what the imaging means.
For my second and final question, I noted that fully a third of the
patients did not have successfully local control. Do you have any
ideas in terms of how either your technique or the technology might
allow us to improve those outcomes? Thank you for allowing me to
review your article.
Dr Lanuti. Thank you, Dr Christie, for your comments. I will
address your last question; that is, why do we have such a high re-
currence rate, and where does that stand among the other observa-
tional studies? In fact, the recurrence rate in our study falls within
the range observed (3%–42%). Three of the local recurrences were
tumors larger than 3 cm. We learned as the experience matured that166 The Journal of Thoracic and Cardiovascular Suthe Covidien cluster electrode has clear size limitations. The limi-
tations of RFA electrode technology are tumor size, proximity to
blood vessels (because they are heat sinks), and the central nature
of the tumor. Although we have treated a single central tumor
with RFA, in general, the tumors selected for this modality have
been peripheral. We had 2 local recurrences resulting from a proce-
dure-related pneumothorax that allowed the lung to move away
from the electrode, because this particular device doesn’t have
the anchoring tines present in the Boston Scientific electrode. Of
note, we had 2 late recurrences, one at 12 months and one at 17
months. The 17-month recurrence was in a patient with previous
lung cancer who refused surgery. His treatment failed at 17 months
after RFA, and he ultimately went to surgery for a salvage right up-
per lobectomy. His final pathologic report showed a 1-cm residual
adenocarcinoma (T1N0) with extensive hyaline fibrosis consistent
with treatment effect.
In summary, our patient population was a heterogeneous group,
similar to all the observational studies previously published. Care-
ful patient selection and understanding the limitations of the tech-
nology will ultimately reduce the recurrence rate. Although our
study population was small, analysis suggests that tumors larger
than 2 cm are more likely to recur locally after RFA with the Covi-
dien cluster electrode.
Dr Bryan FitchMeyers (St Louis, Mo). Dr Lanuti, there is a di-
rect overlap in the indications for this with stereotactic radiation
therapy If I were a patient with inoperable disease, it would just
seem more appealing to get three doses of 20 cGy as an outpatient
rather than having something stuck in my chest. Could you tell me
what the selling points are to a patient to have RFA rather than ste-
reotactic radiation therapy?
Dr Lanuti. That is a good, pertinent, germane question. It is
easy at Massachusetts General in Boston, because we don’t have
any of these CyberKnife or stereotactic radiosurgery programs,
so often we would have to refer them to another institution. That
is an easy answer. Really, though, you are absolutely right; it is
a competitive modality for surgery. I would say that stereotactic ra-
diosurgery does require some interventions. Fiducial markers have
to be placed bronchoscopically, so that it is a procedure. It is three
separate treatments, although relatively benign, as opposed to RFA,
which is a single treatment and then follow-up with multiple scans
and a 23-hour hospital stay. The late complications of stereotactic
radiosurgery in North America relative to Japan as it is emerging
is that the central lesions have much more likelihood of radiation
pneumonitis and bronchial stenosis, and probably Dr Christie could
comment more than I about their own experience. But there are
limitations. So side by side, these modalities would have to be
compared. I think they don’t have to be considered mutually exclu-
sive but actually potentially complementary; RFA is good for cen-
tral necrosis, whereas these external beam radiotherapy techniques
are good for peripheral type treatment.rgery c January 2009
